News
Highlight,Sector Focus,: BridgeBio Pharma operates in the biopharmaceutical sector, with a focus on genetic conditions and oncology.,Insider Actions,: Notable insider share transactions have been ...
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback